RECURSION PHARMACEUTICALS, INC.
RXRX · XNASCIK 1601830fmd_1P9BMY6J0J6GD4E7ZYCBVRS2ESManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 28 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | 2 | 4 | 10 | 40 | 45 | 59 | 75 |
| Cost of revenue | – | 0 | 0 | 48 | 43 | 45 | 71 |
| Gross profit | – | 4 | 10 | (8) | 2 | 14 | 4 |
| Research and development | 46 | 63 | 135 | 156 | 241 | 314 | 475 |
| Total operating expenses | 65 | 89 | 193 | – | – | – | – |
| Operating income | (62) | (85) | (183) | (246) | (350) | (479) | (648) |
| Interest expense | 1 | 1 | 3 | 0 | 0 | 2 | 2 |
| Other non-operating income (expense) | 1 | (2) | (4) | 6 | 18 | 14 | 3 |
| Income before taxes | – | – | (186) | (239) | (332) | (465) | (645) |
| Income tax expense | 0 | 0 | 0 | 0 | (4) | (1) | (0) |
| Net income from continuing operations | – | – | (186) | (239) | (328) | (464) | (645) |
| Net income | (62) | (87) | (186) | (239) | (328) | (464) | (645) |